Articles
News, editorials, patient stories, and more.
This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare provider before making any health decisions. Full Disclaimer
A First-Ever Guideline for Kids With Axial Spondyloarthritis
The American College of Rheumatology released updated treatment guidelines for axial spondyloarthritis in adults, along with the first-ever...
Read More — A First-Ever Guideline for Kids With Axial Spondyloarthritis »
Blog
Best Magnesium Supplements for Hashimoto's Thyroiditis
Fatigue is one of the most persistent and frustrating symptoms for people with Hashimoto's thyroiditis, and it doesn't always resolve fully...
Read More — Best Magnesium Supplements for Hashimoto's Thyroiditis »
Blog
What Is DAS28 and Why Does My Rheumatologist Use It?
Your rheumatologist calls out a number every visit, but rarely explains what it means. DAS28 measures joint tenderness, swelling, inflammati...
Read More — What Is DAS28 and Why Does My Rheumatologist Use It? »A Path Opens for Gut-Focused Treatment in Younger IBD Patients
The FDA has accepted Takeda's application to expand intravenous Entyvio to children as young as 2 with moderate-to-severe ulcerative colitis...
Read More — A Path Opens for Gut-Focused Treatment in Younger IBD Patients »A CAR-T for Lupus Clears the FDA
Imviva Biotech's CTA313, an off-the-shelf CAR-T cell therapy for lupus and other B-cell driven autoimmune diseases, has received FDA clearan...
Read More — A CAR-T for Lupus Clears the FDA »Secukinumab Trial for Giant Cell Arteritis Brings Mixed but Useful Results
The Phase 3 GCAptAIN trial of secukinumab in giant cell arteritis did not meet its main goal of improving sustained remission, but patients...
Read More — Secukinumab Trial for Giant Cell Arteritis Brings Mixed but Useful Results »Experimental Antibody-Lowering Drug Shows Early Promise for Graves' Disease
Early Phase 1b data show Biohaven's BHV-1300 reduced disease-causing TSHR antibodies by more than 80 percent and normalized thyroid hormones...
Read More — Experimental Antibody-Lowering Drug Shows Early Promise for Graves' Disease »A Lab-Engineered Molecule Named Celiacase Could Change How Celiac Disease Is Managed
Researchers in Barcelona have designed a molecule called celiacase that breaks down the most harmful gluten fragments inside the stomach, be...
Read More — A Lab-Engineered Molecule Named Celiacase Could Change How Celiac Disease Is Managed »New Phase 3 Trial Data Show IVIG Improves Outcomes in Autoimmune Encephalitis
Phase 3 data presented at AAN 2026 show that IVIG significantly improves response rates in autoimmune encephalitis patients who do not respo...
Read More — New Phase 3 Trial Data Show IVIG Improves Outcomes in Autoimmune Encephalitis »Nearly One in Four Autoimmune Hepatitis Patients Also Has Another Autoimmune Disease, Study Finds
A new study of 371 autoimmune hepatitis patients found nearly 24 percent also had extrahepatic autoimmune diseases, most commonly Sjogren's...
Read More — Nearly One in Four Autoimmune Hepatitis Patients Also Has Another Autoimmune Disease, Study Finds »
Blog
Best Supplements for Hashimoto's Thyroiditis: What the Evidence Actually Says
Managing Hashimoto's thyroiditis often feels like assembling a puzzle with too many pieces. Thyroid medication is typically the foundation o...
Read More — Best Supplements for Hashimoto's Thyroiditis: What the Evidence Actually Says »Rezpeg Produces Meaningful Hair Regrowth at One Year in Severe Alopecia Areata, Phase 3 Plans Announced
Extended treatment with Nektar Therapeutics' rezpegaldesleukin produced clinically meaningful hair regrowth in 27% of participants with seve...
Read More — Rezpeg Produces Meaningful Hair Regrowth at One Year in Severe Alopecia Areata, Phase 3 Plans Announced »